
CG Oncology, Inc. (NASDAQ:CGON – Free Report) – HC Wainwright issued their Q2 2027 EPS estimates for shares of CG Oncology in a research report issued on Friday, November 6th. HC Wainwright analyst A. Maldonado forecasts that the company will post earnings per share of ($0.93) for the quarter. HC Wainwright currently has a “Buy” rating and a $100.00 target price on the stock. The consensus estimate for CG Oncology’s current full-year earnings is ($3.31) per share. HC Wainwright also issued estimates for CG Oncology’s Q4 2027 earnings at ($0.82) EPS.
Several other brokerages have also issued reports on CGON. Truist Financial boosted their target price on CG Oncology from $82.00 to $85.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Royal Bank Of Canada cut their target price on CG Oncology from $81.00 to $79.00 and set an “outperform” rating on the stock in a research note on Friday, August 7th. Piper Sandler increased their price target on CG Oncology from $82.00 to $85.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of CG Oncology in a research note on Thursday, October 15th. Finally, Wall Street Zen raised CG Oncology from a “strong sell” rating to a “sell” rating in a research note on Saturday. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, CG Oncology presently has an average rating of “Moderate Buy” and an average price target of $87.50.
CG Oncology Price Performance
CG Oncology stock opened at $75.99 on Monday. CG Oncology has a 1-year low of $35.80 and a 1-year high of $80.97. The firm has a market capitalization of $6.74 billion, a P/E ratio of -27.53 and a beta of 0.35. The company’s 50-day moving average is $68.23 and its 200 day moving average is $66.09.
CG Oncology (NASDAQ:CGON – Get Free Report) last released its quarterly earnings results on Friday, November 6th. The company reported ($0.64) EPS for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.19. The firm had revenue of $1.60 million during the quarter, compared to analysts’ expectations of $0.55 million. CG Oncology had a negative net margin of 3,851.09% and a negative return on equity of 24.79%.
Institutional Investors Weigh In On CG Oncology
A number of institutional investors and hedge funds have recently bought and sold shares of CGON. BlackRock Inc. purchased a new stake in shares of CG Oncology in the 2nd quarter worth $444,509,000. Seven Fleet Capital Management LP grew its position in shares of CG Oncology by 24.5% during the 2nd quarter. Seven Fleet Capital Management LP now owns 1,886,236 shares of the company’s stock worth $134,017,000 after buying an additional 371,085 shares in the last quarter. Bank of America Corp DE increased its stake in shares of CG Oncology by 21.8% during the first quarter. Bank of America Corp DE now owns 1,449,364 shares of the company’s stock valued at $98,093,000 after buying an additional 259,311 shares during the period. EcoR1 Capital LLC increased its stake in shares of CG Oncology by 3.5% during the first quarter. EcoR1 Capital LLC now owns 1,102,000 shares of the company’s stock valued at $74,583,000 after buying an additional 37,200 shares during the period. Finally, Jefferies Financial Group Inc. increased its stake in shares of CG Oncology by 8.5% during the third quarter. Jefferies Financial Group Inc. now owns 835,342 shares of the company’s stock valued at $59,217,000 after buying an additional 65,395 shares during the period. 26.56% of the stock is owned by institutional investors.
Insider Activity
In related news, Director Leonard E. Post sold 1,000 shares of the stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $62.06, for a total value of $62,060.00. Following the transaction, the director owned 1,000 shares of the company’s stock, valued at $62,060. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 3,000 shares of company stock valued at $209,580 in the last ninety days. 4.80% of the stock is currently owned by insiders.
More CG Oncology News
Here are the key news stories impacting CG Oncology this week:
- Positive Sentiment: CG Oncology reported a third-quarter loss of $0.64 per share, narrower than analysts’ estimates of about $0.83–$0.86 per share. Zacks earnings report
- Positive Sentiment: Revenue was $1.6 million, above the approximately $0.55 million analysts expected, further supporting the favorable market reaction. CG Oncology Gains on Q3 Results
- Neutral Sentiment: The quarterly loss widened from $0.57 per share a year earlier to $0.64, despite beating current estimates. Investors should weigh that ongoing loss against the earnings and revenue surprises. Zacks earnings report
CG Oncology Company Profile
CG Oncology is a clinical-stage biotechnology company focused on developing treatments for bladder cancer. Based in Irvine, California, the company’s research centers on therapies delivered directly into the bladder.
Its lead investigational therapy, cretostimogene grenadenorepvec (formerly CG0070), is an oncolytic immunotherapy being developed for non-muscle-invasive bladder cancer, including disease that has not responded to Bacillus Calmette-Guérin (BCG) treatment. The modified virus is designed to target cancer cells and stimulate an immune response.
CG Oncology has no approved commercial products.
Read More
- Five stocks we like better than CG Oncology
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
- After the Midterms, Which of These 3 Defense ETFs Looks Strongest?
- The Ugly Truth Behind SoundHound’s Q3 Results
Receive News & Ratings for CG Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CG Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
